• Chief Healthcare ExecutiveChief Healthcare Executive
  • Formulary WatchFormulary Watch
  • Managed Healthcare Executive
  • Medical EconomicsMedical Economics
Managed Healthcare Executive
Managed Healthcare Executive
Resource Centers
View MoreAsthmaAtrial FibrillationBiosimilarsBlood CancerCovid-19DermatologyDigital HealthEye CareHemophiliaHIVLiver DiseaseMultiple SclerosisPost-Acute CarePrescription Digital TherapeuticsRespiratory ConditionsSleep DisordersSubstance Use DisorderType II InflammationUlcerative ColitisVaccines
Spotlight
AMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusExamining Evolving Treatment Paradigms in the Hemophilia B Space Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven ConditionsPBMI National ConferenceUnbranded Biologics: An Overview
Business
View MoreBusiness StrategyChronic DiseaseConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology
News
Media
Expert Interviews
K-Cast
Medical World News
Podcasts
Population Health Perspectives
ConferencesPartners
Publications
MHE Publication
Supplements And Featured Publications
Events
Virtual Events
CME/CE
Resources
PBM Leaders
Sponsored
Sponsored Content
Surveys
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations

© 2023 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Advertisement
Resource CentersSee All >
  • Asthma
  • Atrial Fibrillation
  • Biosimilars
  • Blood Cancer
  • Covid-19
  • Dermatology
  • Digital Health
  • Eye Care
  • Hemophilia
  • HIV
  • Liver Disease
  • Multiple Sclerosis
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Respiratory Conditions
  • Sleep Disorders
  • Substance Use Disorder
  • Type II Inflammation
  • Ulcerative Colitis
  • Vaccines
Spotlight
  • AMCP Annual
  • Asembia’s 2022 Specialty Pharmacy Summit
  • AMCP Nexus
  • Examining Evolving Treatment Paradigms in the Hemophilia B Space
  • Payer Provider Perspectives: Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions
  • PBMI National Conference
  • Unbranded Biologics: An Overview
BusinessSee All >
  • Business Strategy
  • Chronic Disease
  • Consumers
  • Drug Costs
  • Drug Pipeline
  • Formulary
  • Health Management
  • Health/Disease Strategy
  • Hospitals & Providers
  • Industry Analysis
  • Pharmacy
  • Politics and Policy
  • Practice Management
  • Reimbursement
  • Technology
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.

Spinal Muscular Atrophy

  1. home
  2. clinical
  3. spinal-muscular-atrophy
 
James Wymer, MD, FAAN

Updates in Treatment of Adult Spinal Muscular Atrophy

John Brandsema, MD

Challenges and Considerations in Treatment of Adult Spinal Muscular Atrophy

Key opinion leader discusses considerations for adult patients with spinal muscular atrophy (SMA) including disease burden, treatment evaluation, and the use of real-world evidence.

Evolving Landscape of SMA Treatment

December 01, 2022

In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.

Considerations for Payers Covering Combination Treatment of SMA and the Impact of Utilization Management

November 28, 2022

John Brandsema, MD, and Julie Parsons, MD, discuss considerations for combination SMA treatment and factors impacting SMA care pathways, such as prior authorization and multistep therapies.

The Role of Switching and Combination Therapy in SMA Regimens

November 23, 2022

Medical experts provide insights on factors impacting SMA treatment strategies.

Optimizing Treatment of SMA With Disease-Modifying Agents

November 21, 2022

Disease-modifying treatments are highlighted as key contributors to the optimization of SMA management.

Approach to Treatment Selection for Patients with SMA

November 17, 2022

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Economic Burden of SMA

November 14, 2022

Julie Parsons, M.D., and John Brandsema, M.D., explore economic burdens associated with SMA.

Disease-Modifying Therapies Across SMA Treatment Landscape

November 10, 2022

Disease-modifying agents play a significant role in treatment strategies for patients with SMA.

SMA Prevalence and Disease Burden

November 07, 2022

Julie Parsons, MD, and John Brandsema, MD, open a discussion surrounding prevalence of spinal muscular atrophy (SMA).

6 Takeaways From a Review of SMA Prognostic Factors and Treatments

December 16, 2021

Early treatment helps improve the efficacy of treatment of spinal muscular atrophy, according to a comprehensive review article published earlier this month.

A New Way to See Muscle Wasting in Spinal Muscular Atrophy

December 09, 2021

In this diagnostic proof-of-concept trial, an emerging imaging approach that uses a handheld laser demonstrated the ability to visualize muscle degeneration in children with SMA.

Advertisement
Advertisement